Table of Contents
- Why Everyone Is Comparing Retatrutide and Semaglutide
- What Is Semaglutide?
- What Is Retatrutide?
- Retatrutide vs Semaglutide at a Glance
- Which One Wins for Weight Loss?
- How Each One Affects Metabolic Health
- Side Effects and Safety: What to Expect from Each
- Approval Status and Availability
- Which Should You Choose?
- The Bottom Line: Retatrutide vs Semaglutide
Key Takeaways
- Semaglutide received FDA approval for chronic weight management (Wegovy) and type 2 diabetes (Ozempic). Retatrutide is an investigational drug still in Phase 3 clinical trials.
- Retatrutide produced 28.7% average weight loss over 68 weeks in its first Phase 3 readout. Semaglutide's landmark trial showed 14.9% over the same period.
- Semaglutide holds the strongest heart data, with a 20% drop in major adverse cardiovascular events in one large trial.
- Both share similar gastrointestinal symptoms at comparable rates, though retatrutide adds a tingling side effect not seen with semaglutide.
- Anything sold as retatrutide online right now is not the regulated, approved medication. The FDA has stated it cannot be used in compounding under federal law.
Here's the honest answer up front. Retatrutide leads on raw trial numbers, but semaglutide wins on everything you can actually do today.
If you've been comparing the two, you've probably seen wildly different claims. One page says retatrutide melts 30% of body weight. Another says semaglutide remains the safer pick. Meanwhile, some websites sell "retatrutide" that the FDA says can't legally be compounded at all.
Picking wrong costs you months and real money. So let's walk through what the clinical trials actually show, side by side.
Why Everyone Is Comparing Retatrutide and Semaglutide
Think of these three medications as 3 generations of the same idea: using gut hormones to control appetite and blood sugar. Semaglutide came first, working on a single hormone pathway. Then tirzepatide targets two hormone pathways, adding GIP to the mix.
Retatrutide is generation 3, and it goes one further. The tirzepatide and retatrutide mechanism designs share the same base, but retatrutide adds a third receptor on top. Each generation has posted greater weight loss than the one before it, which is why semaglutide and tirzepatide now share headlines with a drug you can't even buy yet.
Both sit at the top of a growing family of best peptides for weight loss reshaping metabolic health. This article stays on the main event: retatrutide vs semaglutide.
What Is Semaglutide?
Semaglutide is an FDA-approved GLP-1 receptor agonist, and it's the active ingredient in Wegovy and Ozempic. Semaglutide targets one receptor that copies a natural gut hormone telling your brain you're full.
In practice, it slows gastric emptying, so food stays in your stomach longer. It helps regulate appetite, supports insulin secretion, reduces glucagon secretion, and steadies blood sugar. Together, those effects deliver appetite control and support weight management without white-knuckle dieting.
The STEP 1 trial published in the New England Journal of Medicine paired the 2.4 mg weekly injection with diet and activity changes. People taking it lost an average of 14.9% of body weight over 68 weeks, while the placebo group lost just 2.4%. That result made semaglutide the benchmark every newer weight loss medication gets measured against.
What Is Retatrutide?
Retatrutide is an investigational medication from Eli Lilly, and retatrutide targets 3 receptors at once: GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon. It is not yet approved, and it's currently moving through Phase 3 clinical trials.
The glucagon piece is what makes it different. While the GLP-1 and GIP pathways handle appetite regulation and fullness signals, glucagon receptors appear to raise energy expenditure and push the body to burn stored fat.
So instead of only eating less, your body may also burn more. That two-sided mechanism explains why early data on retatrutide has the medical community paying close attention.
Retatrutide vs Semaglutide at a Glance
Here are the key differences on the factors that matter most:
| Factor | Semaglutide | Retatrutide |
|---|---|---|
| How it works | GLP-1 receptor agonist (1 pathway) | Triple agonist: GLP-1, GIP, glucagon |
| FDA status | Approved (Wegovy, Ozempic) | Investigational, Phase 3 trials |
| Average weight loss | 14.9% at 68 weeks (STEP 1) | 28.7% at 68 weeks (TRIUMPH-4) |
| Heart data | 20% fewer major cardiac events (SELECT) | Not yet available |
| Dosing | Once weekly injection | Once weekly injection (in trials) |
| Common side effects | Nausea, vomiting, constipation | Similar rates, plus tingling skin sensations in some users |
| Availability | Prescription through a healthcare provider | Clinical trials only |
The one-sentence takeaway: retatrutide roughly doubles the average weight loss, but semaglutide is the only one you can be prescribed today.
Which One Wins for Weight Loss?
On the numbers alone, retatrutide wins. But the numbers deserve context, because the two drugs sit at very different stages of evidence.
What Clinical Trials Show for Semaglutide
Semaglutide's 14.9% result comes from a completed, peer-reviewed trial of nearly 2,000 adults with obesity, or overweight plus at least one weight-related condition. Many patients did even better, with about 1 in 3 losing 20% or more of their body weight.
Its trump card is heart protection. The SELECT trial in the New England Journal of Medicine, which followed 17,604 people with established cardiovascular disease and excess weight but no diabetes, found semaglutide cut major adverse cardiovascular events by 20%. No other drug in this comparison has that proof yet.
What Clinical Trials Show for Retatrutide
Retatrutide's Phase 2 trial reported 24.2% average weight loss at 48 weeks on the 12 mg dose. Then the Phase 3 TRIUMPH-4 trial pushed that to 28.7% at 68 weeks.
In May 2026, Eli Lilly announced topline results from TRIUMPH-1, its pivotal obesity trial. Participants on 12 mg lost an average of 28.3% over 80 weeks, and 45.3% of them lost 30% or more, a level of weight loss long associated with bariatric surgery. Those with severe obesity who continued to 104 weeks averaged 30.3%, though these figures aren't peer reviewed yet.
Keep in mind that no trial has tested these two drugs head to head, so the comparison rests on separate studies. The full retatrutide dosage chart shows how each trial structured its step-by-step titration.
How Each One Affects Metabolic Health
Weight is only part of the story. The bigger picture is metabolic health and overall health, and here retatrutide's third pathway does something remarkable.
In a Phase 2a study, retatrutide reduced liver fat by an average of 86%, with 93% of people on the top dose reaching normal liver fat levels. Researchers credit the glucagon receptors, which tell the liver to burn its stored fat for energy, turning fat loss into a whole-body process rather than a number on the scale.
Semaglutide improves blood sugar, fasting glucose, and cholesterol steadily, with liver fat reductions closer to 15 to 20%. Both help. Retatrutide just appears to hit the liver harder, though that finding still needs Phase 3 confirmation.
Side Effects and Safety: What to Expect from Each
Both medications share the same core gastrointestinal symptoms: nausea, vomiting, diarrhea, and constipation. These usually peak during dose changes and ease as your body adjusts over 4 to 8 weeks.
A few differences stand out.
- Nausea: reported by about 44% of semaglutide users and 42% of retatrutide users at the highest doses in their trials.
- Dysesthesia: a tingling or unusual skin sensation, reported in 12.5% to 20.9% of people on retatrutide's highest dose across Phase 3 trials, versus under 1% on placebo. Most cases were mild and resolved during treatment.
- Heart rate: retatrutide showed dose-dependent increases in heart rate in trials.
- Thyroid warning: semaglutide carries a boxed warning based on preclinical findings. Anyone with a history of medullary thyroid carcinoma should not take it.
- Dehydration: severe vomiting or diarrhea on semaglutide can lead to kidney problems if fluids aren't replaced.
The complete list of retatrutide side effects runs longer than what trials have made headlines for. With either drug, medical oversight matters, since your provider manages titration, appetite changes, and monitoring.
Approval Status and Availability
Semaglutide is available now through any licensed prescriber. Retatrutide isn't on the market yet. Under federal law, the FDA has stated it cannot be used in compounding, so no pharmacy can legally make it for you either. The agency has also warned companies selling versions falsely labeled "for research purposes" directly to consumers.
The path forward is clearer than it sounds. Retatrutide's Phase 3 TRIUMPH trials keep reporting results through 2026, and once approval comes, the real version reaches you the same way semaglutide does today, through a prescription from your doctor filled at a state-licensed pharmacy.
Which Should You Choose?
There's no single right answer here, just the right fit for your weight loss journey. Talk it through with your healthcare provider, and use this as a starting point.
Semaglutide fits you if any of these sound familiar.
- You want an FDA-approved option with insurance coverage pathways today
- You have established cardiovascular disease and want the proven heart benefit
- You prefer gradual weight loss with the longest real-world track record
Waiting for retatrutide makes sense in a different situation.
- Earlier weight loss medications didn't move the needle enough
- Fatty liver is part of your health picture
- You'd rather hold out for the strongest numbers ever recorded in a weight loss trial
No matter which direction matches your health goals, both drugs work best alongside healthy eating and regular physical activity.
The Bottom Line: Retatrutide vs Semaglutide
Retatrutide posts the strongest average weight loss any trial has recorded, nearly double semaglutide's benchmark. Its triple-pathway design, especially the glucagon effect on fat reduction and energy expenditure, looks like the future of this drug class.
But semaglutide remains the practical winner right now. It's FDA-approved, backed by heart-outcome data, available through medical weight management programs, and supported by years of real-world use.
So the fair verdict is semaglutide today, with retatrutide worth watching closely. The best choice is always the one made with your doctor, based on your health history and goals.
Frequently Asked Questions
Is retatrutide more effective than semaglutide?
Based on separate trials, yes. Retatrutide produced 28.7% average weight loss at 68 weeks in Phase 3, while semaglutide produced 14.9% over the same period. No head-to-head trial has directly compared them yet, so treat the gap as strong early data rather than settled fact.
Is retatrutide better than Ozempic?
Ozempic is simply semaglutide approved for type 2 diabetes, so the trial comparison above applies. Retatrutide shows greater weight loss in its studies, but Ozempic is approved, available, and proven for blood sugar control today. Better depends on what you need and when you need it.
Is it okay to switch from semaglutide to retatrutide?
Not yet, because retatrutide isn't available outside clinical trials. Once it earns FDA approval, switching would be a decision for your healthcare provider based on your progress and dose history, and a peptide dosage calculator can help you follow the unit conversions in any protocol discussion. Never switch to a version sold online, since it sits outside the regulated supply chain.
Who should not use retatrutide?
Anyone outside a clinical trial, for now. Once approved, it will likely carry restrictions similar to semaglutide, including the warning for people with a history of medullary thyroid carcinoma. Your doctor will screen your medical history before prescribing anything in this class.
This article is for educational purposes only and is not medical advice. Retatrutide is an investigational medication and is not yet approved for use. Always consult a licensed healthcare professional before starting, stopping, or changing any medication or supplement.
